http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
CRNA Week Celebrates 'Heart of Anesthesia'
-
South Carolina Recognizes CRNA Week
-
Leviton Showcases Fiber Platforms for AI Data Centers and Extended Distance Copper Solutions for Enterprise Applications at BICSI Winter 2026
-
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
-
Cardiovascular Logistics Appoints Steve Brumfield as Vice President of Accounting and Controller
-
Trailbreaker Receives Drill Permit for Coho Property, Central BC
-
JCDecaux : Disclosure of transactions in own shares
-
CAE names Ryan McLeod as chief financial officer
-
CAE announces appointment of Ryan McLeod as Chief Financial Officer
-
MSV Protocol Launches Proof-of-Asset Integrity to Strengthen Real-World Asset Tokenisation as RWA Adoption Accelerates
-
Italian Wine Podcast Renews Media Partnership with Grandi Langhe Wine Festival
-
Italian Wine Podcast Renews Media Partnership with Grandi Langhe Wine Festival
-
Apex Summarizes Progress to-date and 2026 Outlook at the Rift Rare Earth Project
-
Kickstart 2026 Trading at Bitrue
-
Kickstart 2026 Trading at Bitrue
-
NeoBio.ai Launches AI-Native Ecosystem to Build a Long-Term Value Circulation Structure
-
FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
-
Darkness to Light Releases 2025 Impact Report Detailing New Data on Child Sexual Abuse Prevention
-
AKEDO Raises 5 Million USD Seed Round to Build an AI-Native Content Creation Engine and Launchpad Powered by Multi-Agent Systems
-
AKEDO Raises 5 Million USD Seed Round to Build an AI-Native Content Creation Engine and Launchpad Powered by Multi-Agent Systems
-
WOW Exchange Officially Launches Upcoming New Cryptocurrency Trading Platform for Transparency, Security, & Smarter Market Access
-
WOW Exchange Officially Launches Upcoming New Cryptocurrency Trading Platform for Transparency, Security, & Smarter Market Access
-
WOW Exchange Officially Launches Upcoming New Cryptocurrency Trading Platform for Transparency, Security, & Smarter Market Access
-
Fundera Network Launches AI-Powered Platform Built for Clarity
-
Ethereum (ETH) Up 7% This Week, yet Top Traders Secure GeeFi (GEE) as $1.5K Can Become $45K in Months
-
Solana (SOL) Reaches $147, but Analysts Predict GeeFi (GEE) Can Return Over $45K from $1.5K this Altcoin Season
-
CDN Maverick Announces Normal Course Issuer Bid
-
Avalanche (AVAX) Holders Are Moving to GeeFi (GEE): Experts Predict Over 2,900% ROI This Alcoin Season After Roadmap Update
-
Silver North Announces Further Upsize of Brokered LIFE Private Placement for Gross Proceeds of up to C$10.6 Million
-
Bloom: Celebrating AHF’s Activism Through Augmented Reality and Art
-
Repare shareholders approve acquisition by XenoTherapeutics
-
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
-
BlackRock to Change Primary Listing Venue for Four iShares ETFs
-
PRI Files Amicus Brief in Major Supreme Court Case That Could Upend Future Medical Innovation Nationwide
-
Conduent names Harsha Agadi as CEO, replacing Cliff Skelton
-
Conduent Appoints Harsha V. Agadi as Chief Executive Officer
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
GeeFi (GEE) Rolls Out New Wallet and Roadmap Update, Analysts Forecast 2,900% ROI in 2026
-
The Price is Right Live™ is coming to a town near you starting January 30 to May 10, 2026
-
VALUE LINE, INC. DECLARES A QUARTERLY CASH DIVIDEND OF $0.325 PER COMMON SHARE AND APPOINTS NEW BOARD MEMBER
-
Woods Lonergan PLLC Awarded 2026 Chambers & Partners New York Spotlight for Litigation: General Commercial
-
AbbVie reports mixed results for lymphoma drug in phase 3 trial
-
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
-
Rubrik launches security cloud with data sovereignty controls
-
Rubrik Announces Rubrik Security Cloud Sovereign
-
Liberty Sports Group Announces Strategic Partnership with Austin Rise FC as Club Prepares for Transition to Tier Two Women's Professional Soccer
-
Canadian Securities Exchange Reports Strong 2025 Performance Figures
-
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
-
Join First Phosphate's Exclusive Live Investor Webinar and Q&A Session on January 22

